ESPCG Annual Report 2004

Gastro-intestinal complaints in primary care across Europe

Publications by ESPCG committee members from 2005.

General abdominal complaints

Aro P, Ronkainen J, Talley NJ, Storskrubb T, Bolling-Sternevald E, Agréus L. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut. 2005;54:1377-83

Van den Heuvel-Janssen HAM, Borghouts JA, Muris JWM, Koes BW, Bouter LM, Knottnerus JA. Chronic non-specific abdominal complaints in general practice: a prospective study on management, health status and course of complaints. BMC Family Practice 2006; 7(1): 12

Seifert B, Lukás K, Charvátová E, Vojtísková J, Koudelka T, Hep A, Bures J, Jirásek V, Díte P. [Lower dyspeptic syndrome. Recommended diagnostic and therapeutic procedures for general practitioners 2006]. Cas Lek Cesk. 2007;146(1):17-23.

Wensaas K-A, Langeland N, Rørtveit G. [Uncovering the giardiasis-outbreak in Bergen 2004.] Tidsskr Nor Laegeforen 2007;127:2222-5

Ålander T, Heimer G, Svärdsudd K, Agréus L. Abuse in Women and Men with and without Functional Gastrointestinal Disorders. Dig Dis Sci. 2008;53:1856-64.

Ålander T, Svärdsudd K, Agréus L. Functional gastrointestinal disorder is associated with increased non-gastrointestinal healthcare consumption in the general population. Int J Clin Pract. 2008;62:234-40.

Bolling-Sternevald E, Aro P, Ronkainen J, Storskrubb T, Talley NJ, Junghard O, Agréus L. Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study. Dig Dis. 2008;26:256-63.

Jones R, Rubin G, Berenbaum F, Scheiman J. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med. 2008 Jun;121(6):464-74. Review.

McDougall P, Drewett RF,HunginAP, Wright CM. The detection of early weight faltering at the 6-8 week check and its association with family factors, feeding and behavioural development. Arch Dis Child. 2009 Jul;94(7):549-52.

Mørch K, Hanevik K, Rortveit G, Wensaas K-A, Langeland N. High rate of fatigue and abdominal symptoms two years after an outbreak of giardiasis. Trans R Soc Trop Med Hyg 2009;103:530-2

Wensaas K-A, Langeland N, Rortveit G. Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area. Scand J Prim Health Care 2009; 27:12-7

Mørch K, Hanevik K, Rortveit G, Wensaas K-A, Eide GE, Hausken T, Langeland N. Risk factors for fatigue and abdominal symptoms and fatigue two years after Giardia lamblia infection. BMC Infect Dis. 2009 Dec 15;9:206.

Wensaas K-A, Langeland N, Rortveit G. Post-infectious gastrointestinal symptoms after acute Giardiasis. A one-year follow-up in general practice. Fam Pract. 2010;27:255-9.

Ungan M;Gastrointestinal Problems Among University Students, are They Different Than the Population? Turkiye Klinikleri J Fam Med-Special Topics 2010;1(3):49-52

Mørch K, Hanevik K, Rivenes AC, Bødtker J, Næss H, Stubhaug B, Wensaas KA, Rortveit G, Eide GE, Hausken T, Langeland N. Chronic Fatigue Syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterol. 2013;13:28

E. Oikonomidou,F. Anastasiou,C. Mihas,S. Dimopoulou,A. Glystra,I. Tsiligianni,G. Kolios,H. Kouroumalis,C. Lionis. Identification and management of patients with upper gastrointestinal symptoms in the primary care setting. Arch Hellen Med, 30(3), May-June 2013, 309-315

Rajasekhar P, Ritchie M, Rutter M, Clifford G, Waddup G, Dempsey N, Rubin G, Rees C. Lower gastrointestinal symptoms are prevalent among individuals colonoscoped within the Bowel Cancer Screening Programme. Colorectal Disease 2012.

Alam SE, Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Dharwadkar S, Wilson D,HunginP. Nutritional aspects of epigenetic inheritance. Can J Physiol Pharmacol. 2012 Aug;90(8):989-994. Review.

Walter SA, Jones MP, Talley NJ, Kjellstrom L, Nyhlin H, Andreasson AN, Agréus L. Abdominal pain is associated with anxiety and depression scores in a sample of the general adult population with no signs of organic gastrointestinal disease. Neurogastroenterol Motil. 2013;25:741-e576.

Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, Guarner F, Katelaris P, Smout A, Umar M, Whorwell P, Johanson J, Saenz R, Besançon L, Ndjeuda E, Horn J,HunginP, Jones R, Krabshuis J, LeMair A; Review Team. Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating and abdominal pain/discomfort. J Clin Gastroenterol. 2014 Aug;48(7):567-578

Diagnosis

Schussele Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I, Arditi C, Delvaux M, Numans ME, Lorenzo-Zuniga V, Dubois RW, Juillerat P, Burnand B, Pittet V, Vader JP, Froehlich F, EPAGE II Study Group (Agréus L). Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating. Endoscopy. 2009;41:234-9.

Peytremann-Bridevaux I, Arditi C, Froehlich F, O'Malley J, Fairclough P, Le Moine O, Dubois RW, Gonvers JJ, Schussele Filliettaz S, Vader JP, Juillerat P, Pittet V, Burnand B, EPAGE II Study Group (Agréus L.) Appropriateness of colonoscopy in Europe (EPAGE II). Iron-deficiency anemia and hematochezia. Endoscopy. 2009;41:227-33.

Schussele Filliettaz S, Juillerat P, Burnand B, Arditi C, Windsor A, Beglinger C, Dubois RW, Peytremann-Bridevaux I, Pittet V, Gonvers JJ, Froehlich F, Vader JP, EPAGE II Study Group (Agréus L). Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009;41:218-26.

Arditi C, Gonvers JJ, Burnand B, Minoli G, Oertli D, Lacaine F, Dubois RW, Vader JP, Schussele Filliettaz S, Peytremann-Bridevaux I, Pittet V, Juillerat P, Froehlich F, EPAGE II Study Group (Agréus L.) Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and after resection of colorectal cancer. Endoscopy. 2009;41:209-17.

Arditi C, Peytremann-Bridevaux I, Burnand B, Eckardt VF, Bytzer P, Agréus L, Dubois RW, Vader JP, Froehlich F, Pittet V, Schussele Filliettaz S, Juillerat P, Gonvers JJ. Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. Endoscopy. 2009;41:200-8.

Jones R, Rubin G. Acute diarrhoea in adults. BMJ. 2009 Jun 15;338:b1877.

Molinder HK, Kjellström L, Nylin HB, Agréus LE. Doubtful outcome of the validation of the Rome II questionnaire: validation of a symptom based diagnostic tool. Health Qual Life Outcomes. 2009;7:106.

Walter SA, Kjellström L, Talley NJ, Andreasson AN, Nyhlin H, Agréus L. Prospective diary evaluation of unexplained abdominal pain and bowel dysfunction: a population-based colonoscopy study. Dig Dis Sci. 2011;56:1444-51.

Kok L, Elias SG, Witteman BJ, Goedhard JG, Muris JW, Moons KG, de Wit NJ.Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) Study. Clin Chem. 2012 Jun;58(6):989-98.

GORD

General

Quigley EM, Hungin AP. Review article: quality-of-life issues in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:41-7. Review

Mason J, Hungin AP. Review article: gastro-oesophageal reflux disease--the health economic implications.Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:20-31. Review

Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-31.

Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Graffner H, Vieth M, Stolte M, Engstrand L, Talley NJ, Agréus L. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275-85.

Ronkainen J, Aro P, Storskrubb T, Lind T, Bolling-Sternevald E, Junghard O, Talley NJ, Agréus L. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. Aliment Pharmacol Ther. 2006;23:1725-33.

Roger Jones; Greg Rubin; Niek de Wit; Bohumil Seifert; Lars Agreus Gastro-oesophageal reflux redefined; implications for primary care. Eur J of Gen Pract.2007; (13) 4:: 214-5

Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Walker MM, Agréus L. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut. 2007;56:615-20.

Dent J, Kahrilas PJ, Vakil N, Van Zanten SV, Bytzer P, Delaney B, Haruma K, Hatlebakk J, McColl E, Moayyedi P, Stanghellini V, Tack J, Vaezi M. Clinical trial design in adult reflux disease: a methodological workshop. Aliment Pharmacol Ther. 2008 Jul;28(1):107-26.

AW. van der Velden, NJ. de Wit, AO Quartero DE. Grobbee ME. Numans. Maintenance treatment for GERD: residual symptoms are associated with psychological distress. Digestion 2008: 77; 207-13.

Delaney B, Moayyedi P. GORD in adults. Clin Evid (Online). 2008 Jun 13;2008

Åsling B, Jirholt J, Hammond P, Knutsson M, Walentinsson A, Davidson G, Agréus L, Lehmann A, Lagerstrom-Fermer M. Collagen type III alpha I (COL3A1) is a Gastro-oesophageal reflux disease (GORD) susceptibility gene and a male risk factor for hiatus hernia (HH). Gut. 2009;26:26.

Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agréus L, Jablonowski H, Zapardiel J. Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health Qual Life Outcomes. 2009;7:60

Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agréus L, Jablonowski H, Tafalla M. Management of gastro-oesophageal reflux disease in primary care: a European observational study. Curr Med Res Opin. 2009;25:2777-84.

Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agréus L, Jablonowski H, Tafalla M. Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. Eur J Gen Pract. 2009;15:154-60.

Alike vd Velden,Niek J de Wit, A Otto Quartero, Diederick E Grobbee, Mattijs E Numans. GORD patients on chronic acid suppressive medication: A population average psychological state. Scand J Gastroenterol 2009; 44: 380-82.

van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans E.Pharmacological Dependency in Chronic Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Clinical Trial. Digestion. 2010;81(1):43-52.

Flameling RD, Numans ME, Ter Linde J, de Wit NJ, Siersema PD. Different characteristics of patients with gastro-oesophageal reflux disease on their path through healthcare: a population follow-up study. Eur J Gastroenterol Hepatol. 2010 May;22(5):578-822.

Kanwal F, Barkun A, Gralnek IM, Asch SM, Kuipers EJ, Bardou M, Sung J, Enns R, Agréus L, Armstrong D, Spiegel BM. Measuring quality of care in patients with nonvariceal upper gastrointestinal hemorrhage: development of an explicit quality indicator set. Am J Gastroenterol. 2010;105:1710-8.

Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P, Agréus L (in Collaborators) . International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101-13.

Ronkainen J, Talley NJ, Storskrubb T, Johansson SE, Lind T, Vieth M, Agreus L, Aro P. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106:1946-52

Jirholt J, Åsling B, Hammond P, Davidson G, Knutsson M, Walentinsson A, Jensen JM, Lehmann A, Agréus L, Lagerström-Fermer M. 4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease. PLoS One. 2011;6:e19095.

Close H, Mason JM, Wilson D,HunginAP. Hormone replacement therapy is associated with gastro- oesophageal reflux disease: a retrospective cohort study. Gastroenterol. 2012 May 29;12:56.

Forssell L, Cnattingius S, Bottai M, Edstedt Bonamy AK, Lagergren J, Agréus L, Akre O. Increased Risk of Barrett's Esophagus Among Individuals Born Preterm or Small for Gestational Age. Clin Gastroenterol Hepatol. 2013;11:790-4.

Forssell L, Cnattingius S, Bottai M, Edstedt Bonamy AK, Lagergren J, Agréus L, Akre O. Risk of oesophageal adenocarcinoma among individuals born preterm or small for gestational age.Eur J Cancer. 2013 Jun;49(9):2207-13. doi: 10.1016/j.ejca.2013.02.014. Epub 2013 Mar 13. Erratum in: Eur J Cancer. 2013 Oct;49(15):3385.

Forssell L, Cnattingius S, Bottai M, Lagergren J, Ekbom A, Akre O.Risk of esophagitis among individuals born preterm or small for gestational age. Clin Gastroenterol Hepatol. 2012 Dec;10(12):1369-75.

Akre O, Forssell L, Kaijser M, Norén-Nilsson I, Lagergren J, Nyrén O, Ekbom A. Perinatal risk factors for cancer of the oesophagus and gastric cardia: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):867-71.

HunginAP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: Patterns of proton pump inhibitor use and adherence in gaastroesophageal reflux disease.Clin Gastroenterol Hepatol. 2012 Feb;10(2):109-16.

Ruigómez A,HunginAP, Lundborg P, Johansson S, Wallander MA, García Rodríguez LA. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.Eur J Gastroenterol Hepatol. 2011 Mar;23(3):232-7.

HunginAP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro- oesophageal reflux disease and dyspepsia.Aliment Pharmacol Ther. 2009 Aug 15;30(4):331-42.

Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Heading RC, Holtman G, Moss SF; Vevey NERD Consensus Group. Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group.Digestion. 2009;80(2):74-88.

HunginAP, Modlin I.NERD: a new approach in managing reflux symptoms.Fam Pract. 2008 Dec;25(6):397-9.

Diagnosis

Jones R, Galmiche JP. Review: what do we mean by GERD?--definition and diagnosis. Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:2-10.

Rubin G, Uebel P, Brimo-Hayek A, Hey KH, Doerfler H, Heading RC. Validation of a brief symptom questionnaire (ReQuest in Practice) for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008 May;27(9):846-51

Treatment

Raghunath AS,HunginAP, Mason J, Jackson W.Symptoms in patients on long – term proton pump inhibitors: Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther. 2009 Feb 15;29(4):431-9.

Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P,HunginAP, Batchelor HK.New algorithm for the treatment of gstro-oesophageal reflux disease.Aliment Pharmacol Ther. 2008 Feb 1;27(3):249-56.

Dyspepsia

General

Delaney B, Ford AC, Forman D, Moayyedi P, Qume M. Initial management strategies for dyspepsia. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001961. Review.

Agréus L, Talley NJ, Sheen A, Johansson SE, Jones MP, Svärdsudd K. Predictors and non-predictors of symptom relief in dyspepsia consultations in primary care. Dig Dis. 2008;26:248-55.

Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agréus L. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol. 2008;43:1448-55.

Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agréus L. Duodenal mastocytosis, eosinophilia and intra-epithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;17:17.

Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P. Clinical use of proton-pump inhibitors but not H(2)-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol. 2009;4:1-7.

Fransen GA, Janssen MJ, Muris JW, Mesters I, Knottnerus JA. Measuring the severity of upper gastrointestinal complaints: does GP assessment correspond with patients' self-assessment? Fam Pract. 2007;24(3):252-8.

Fransen GA, van Marrewijk CJ, Mujakovic S, Muris JW, Laheij RJ, Numans ME, de Wit NJ, Samsom M, Jansen JB, Knottnerus JA. Pragmatic trials in primary care. Methodological challenges and solutions demonstrated by the DIAMOND-study. BMC Med Res Methodol. 2007 Apr 23;7:16. Review.

Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The Short-Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther. 2007 Feb 15;25(4):477-86.

Hawkey CJ, Jones RH, Yeomans ND, Scheiman JM, Talley NJ, Goldstein JL, Ahlbom, H, Naesdal J. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2007 Apr 1;25(7):813-21.

Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Naesdal J, Yeomans ND; NASA/SPACE author group. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther. 2007;9(1):R17.

Mujakovic S, de Wit NJ, van Marrewijk CJ, Fransen GA, Laheij RJ, Muris JW,

Samsom M, Grobbee DE, Jansen JB, Knottnerus JA, Numans ME. Psychopathology is associated with dyspeptic symptom severity in primary care patients with a new episode of dyspepsia. Aliment Pharmacol Ther. 2009; 29(5):580-8.

Van Marrewijk CJ, VAN Oijen MG, Paloheimo LI, Fransen GA, Mujakovic S, Muris JW, Numans ME, DE Wit NJ, Grobbee DE, Knottnerus JA, Laheij RJ, Jansen JB. Influence of gastric mucosal status on success of stepwise acid suppressive therapy for dyspepsia. Aliment Pharmacol Ther. 2009 Mar 21.

Fransen GA, Mesters I, Janssen MJ, Knottnerus JA, Muris JW. Which

patient-related factors determine self-perceived patient adherence to prescribed dyspepsia medication?. Health Educ Res. 2009 Mar 20.

Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johannsson SE, Bolling-Sternevald E, Agreus L. Anxiety is associated with uninvestigated and functional dyspepsia (ROME III criteria) in a Swedish population-based study. Gastroenterology. 2009;26:26.

Oikonomidou E, Anastasiou F, Pilpilidis I, Kouroumalis E, Lionis C; GreekGeneral Practice Dyspepsia Group*. Upper gastrointestinal endoscopy fordyspepsia: Εxploratory study of factors influencing patient compliance in Greece.BMC Gastroenterol. 2011 Feb 14;11:11.

Aro P, Talley NJ, Agréus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, Ronkainen J. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011;33:1215-24.

Epidemiology

Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, Stolte M, Talley NJ, Agréus L. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol. 2006;163:1025-34.

Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agréus L. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1175-83

Mujakovic S, DE Wit NJ, VAN Marrewijk CJ, Fransen GA, Laheij RJ, Muris JW,Samsom M, Grobbee DE, Jansen JB, Knottnerus JA, Numans ME. Psychopathology is associated with dyspeptic symptom severity in primary care patients with a new episode of dyspepsia. Aliment Pharmacol Ther.2009 Mar 1;29(5):580-8

Diagnosis

Anastasiou F, Antonakis N, Chaireti G, Theodorakis PN, Lionis C. Identifying dyspepsia in the Greek population: translation and validation of a questionnaire. BMC Public Health. 2006 Mar 4;6:56.

Hungin AP, Seifert B. Upper gastrointestinal endoscopy or not, and in whom? Eur J Gastroenterol Hepatol. 2007 Jul;19(7):527-8. Review.

Mujakovic S, ter Linde JJ, de Wit NJ, van Marrewijk CJ, Fransen GA,Onland-Moret NC, Laheij RJ, Muris JW, Grobbee DE, Samsom M, Jansen JB, KnottnerusA, Numans ME. Serotonin receptor 3A polymorphism c.-42C > T is associated withsevere dyspepsia. BMC Med Genet. 2011 Oct 20;12:140.

Treatment

Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001960. Review.

Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome.Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006442.

Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009 Aug 27;339:

van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H(2)-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.Lancet. 2009 Jan 17;373(9659):215-225.

Smeets HM, De Wit NJ, Delnoij DM, Hoes AW.. Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care. Eur J Gen Pract. 2009 Dec;15(4):219-25.

Smeets HM, de Wit NJ, Zuithoff NP, van Dijk PC, van der Lee AP, Hoes AW. A health insurance company-initiated multifaceted intervention for optimizing acid-suppressing drug prescriptions in primary care: a randomized controlled trial. Arch Intern Med. 2010 Jul 26;170(14):1264-8.

Smeets HM, Hoes AW, Zuithoff NP, van Dijk PC, van der Lee AP, de Wit NJ. Ahealth insurance company-initiated practice support intervention for optimizingacid-suppressing drug prescriptions in primary care. Eur J Gastroenterol Hepatol.2011 Jun 13. [Epub ahead of print]

Fransen GA, Mesters I, Muris JW, Van Marrewijk CJ, Mujakovic S, Laheij RJ,